Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 120
11
Diseases
35
Unique genes
0.152
Avg. similarity score
Colchicine resistance
Most-connected disease (6 links)
Disease
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Colchicine resistance
Familial mediterranean fever
Antisocial personality disorder
Orthostatic hypotension
Congenital dyserythropoietic anemia
Hematologic neoplasms
Hyperpituitarism
Brunner syndrome
Dopamine beta-hydroxylase deficiency
Separation anxiety disorder
anemia, congenital dyserythropoietic, type 1a
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Colchicine resistance | 6 | 6 | 1 |
| Familial mediterranean fever | 6 | 6 | 2 |
| Antisocial personality disorder | 5 | 5 | 4 |
| Orthostatic hypotension | 4 | 4 | 3 |
| Congenital dyserythropoietic anemia | 3 | 3 | 10 |
| Hematologic neoplasms | 3 | 3 | 5 |
| Hyperpituitarism | 3 | 3 | 15 |
| Brunner syndrome | 1 | 1 | 1 |
| Dopamine beta-hydroxylase deficiency | 1 | 1 | 2 |
| Separation anxiety disorder | 1 | 1 | 1 |
| anemia, congenital dyserythropoietic, type 1a | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| ABCB1 | 7 / 11 | Antisocial personality disorder, Colchicine resistance, Congenital dyserythropoietic anemia, Familial mediterranean fever and 3 more |
| CDAN1 | 2 / 11 | anemia, congenital dyserythropoietic, type 1a, Congenital dyserythropoietic anemia |
| DRD4 | 2 / 11 | Antisocial personality disorder, Separation anxiety disorder |
| HSPA5 | 2 / 11 | Dopamine beta-hydroxylase deficiency, Hematologic neoplasms |
| MAOA | 2 / 11 | Antisocial personality disorder, Brunner syndrome |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Defective MAOA causes Brunner syndrome (BRUNS) | Reactome | 1 / 1 | 343× | 2.91e-3 | 3.01e-2 ✓ sig. |
| Interleukin-4 and Interleukin-13 signaling | Reactome | 3 / 108 | 9.5× | 3.75e-3 | 3.60e-2 ✓ sig. |
| Tyrosine metabolism | KEGG | 2 / 36 | 19.1× | 4.88e-3 | 4.32e-2 ✓ sig. |
| G alpha (i) signalling events | Reactome | 4 / 249 | 5.5× | 5.70e-3 | 4.78e-2 ✓ sig. |
| Enzymatic degradation of Dopamine by monoamine oxidase | Reactome | 1 / 2 | 172× | 5.82e-3 | 4.84e-2 ✓ sig. |
| Metabolism of serotonin | Reactome | 1 / 2 | 172× | 5.82e-3 | 4.84e-2 ✓ sig. |
| Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB | Reactome | 1 / 2 | 172× | 5.82e-3 | 4.84e-2 ✓ sig. |
| Tryptophan metabolism | KEGG | 2 / 42 | 16.3× | 6.60e-3 | 5.27e-2 |
| Mitotic Telophase/Cytokinesis | Reactome | 1 / 3 | 114× | 8.72e-3 | 6.31e-2 |
| Enzymatic degradation of dopamine by COMT | Reactome | 1 / 3 | 114× | 8.72e-3 | 6.31e-2 |
| IRE1alpha activates chaperones | Reactome | 1 / 3 | 114× | 8.72e-3 | 6.31e-2 |
| Opioid Signalling | Reactome | 1 / 3 | 114× | 8.72e-3 | 6.31e-2 |
| Catecholamine biosynthesis | Reactome | 1 / 4 | 85.8× | 1.16e-2 | 7.50e-2 |
| ATF6 (ATF6-alpha) activates chaperones | Reactome | 1 / 4 | 85.8× | 1.16e-2 | 7.50e-2 |
| IRAK4 deficiency (TLR5) | Reactome | 1 / 4 | 85.8× | 1.16e-2 | 7.50e-2 |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| behavioral response to ethanol | GO:0048149 | 3 / 10 | 160× | 7.16e-7 | 6.34e-5 ✓ sig. |
| G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | GO:0007187 | 4 / 54 | 39.5× | 3.05e-6 | 2.02e-4 ✓ sig. |
| cellular response to alkaloid | GO:0071312 | 2 / 6 | 178× | 5.09e-5 | 1.82e-3 ✓ sig. |
| fear response | GO:0042596 | 2 / 8 | 133× | 9.48e-5 | 2.90e-3 ✓ sig. |
| G protein-coupled opioid receptor signaling pathway | GO:0038003 | 2 / 9 | 119× | 1.22e-4 | 3.51e-3 ✓ sig. |
| mitotic spindle midzone assembly | GO:0051256 | 2 / 11 | 97.1× | 1.85e-4 | 4.79e-3 ✓ sig. |
| dopamine catabolic process | GO:0042420 | 2 / 11 | 97.1× | 1.85e-4 | 4.79e-3 ✓ sig. |
| cerebellar Purkinje cell layer development | GO:0021680 | 2 / 12 | 89.0× | 2.22e-4 | 5.43e-3 ✓ sig. |
| erythrocyte differentiation | GO:0030218 | 3 / 65 | 24.6× | 2.43e-4 | 5.79e-3 ✓ sig. |
| maternal behavior | GO:0042711 | 2 / 14 | 76.3× | 3.06e-4 | 6.81e-3 ✓ sig. |
| adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | GO:0007193 | 3 / 73 | 21.9× | 3.42e-4 | 7.35e-3 ✓ sig. |
| vasoconstriction | GO:0042310 | 2 / 18 | 59.3× | 5.12e-4 | 9.70e-3 ✓ sig. |
| hematopoietic stem cell proliferation | GO:0071425 | 2 / 25 | 42.7× | 9.95e-4 | 1.50e-2 ✓ sig. |
| acyl-CoA metabolic process | GO:0006637 | 2 / 28 | 38.1× | 1.25e-3 | 1.73e-2 ✓ sig. |
| interleukin-1-mediated signaling pathway | GO:0070498 | 2 / 28 | 38.1× | 1.25e-3 | 1.73e-2 ✓ sig. |